What Oxford Immune Algorithmics does

Oxford Immune Algorithmics (OIA) is a UK-based medical device company developing the Algocyte platform for at-home blood diagnostics. Its flagship product, Algocyte Proxima, is a CE-marked dual-sensor hematological analyser that converts physical sensor signals into blood test results in minutes, replacing the conventional clinical-visit-and-lab model. The device is paired with the Algocyte Health Hub companion app (Bluetooth-controlled) and single-use, cold-chain-free CE-marked cartridges. Underlying the device is a patented physics-informed AI architecture, described as quantum mechanics-inspired and anchored in physics and biology rather than pure data-driven methods, with US Patents 11175230 and 11534751 protecting the approach. The company was incubated at Oxford University and spun out from King's College London, with clinical leadership rooted in NHS and Cambridge ecosystems.

The company targets five primary customer segments: (1) healthcare providers and NHS hospital-at-home programs seeking decentralized monitoring, (2) oncology pathways requiring regular full blood count monitoring for treatment continuity, (3) community psychiatry services requiring clozapine patient monitoring, (4) domiciliary and care home providers, and (5) individual consumers and families seeking personal health intelligence. Secondary segments include payors (value-based care outcome data) and pharmaceutical companies (decentralized clinical trials). The revenue model is a hardware-plus-consumables-plus-subscription architecture: device sales, recurring single-use cartridge revenue, and ongoing app/dashboard subscription services.

OIA's go-to-market combines enterprise field sales to healthcare providers and NHS trusts, event-driven demand generation (including a flagship Royal Society of Medicine launch on June 29, 2026), direct-to-consumer self-serve distribution through the Health Hub app, and a content-led awareness strategy. The company holds ISO 13485, ISO/IEC 27001:2022, Cyber Essentials Plus, and UKCA certifications, and is an Official NHS Partner (featured in the NHS 75th Anniversary book). Approximately $7.13 million has been raised across two 2021 funding rounds; no subsequent financing or commercial revenue is publicly disclosed. The Health Hub's future release will introduce baseline learning and trend analysis against a dataset of 120M+ aggregated blood test results to support differential diagnosis, expanding the platform beyond diagnostic hardware into longitudinal health intelligence.

Name

Oxford Immune Algorithmics

Legal name

Oxford Immune Algorithmics Ltd.

Website

https://immunealgorithmics.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Oxford Immune Algorithmics develops the Algocyte Proxima, a CE-marked at-home dual-sensor hematological analyser using patented physics-informed AI to deliver blood test results in minutes. It serves NHS providers, oncology and clozapine clinics, payors, pharma, and consumers via a hardware-plus-consumables-plus-subscription model.

Ownership category

akta.pro rank

Product category

Medical Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

akta.pro secondary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

Keywords

• At-home blood testing
• Physics-informed AI diagnostics
• Haematological analyser devices
• Decentralized healthcare monitoring
• Medical diagnostics cartridges

Headquarters

HQ city

Reading

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Hardware Device Sales: Sale of the Algocyte Proxima device - a hardware medical device for at-home blood testing.
2. Consumables (Test Kits/Cartridges): Single-use CE-marked cartridges required for each test. Recurring consumable revenue tied to testing frequency.
3. Subscription Services: Ongoing subscription for app access, data analysis, trend monitoring, and clinical dashboard services.

Go-to-market motion4 records

Distribution channels5 records

Marketing channels6 records

Core offering

Oxford Immune Algorithmics (Algocyte) sells the Algocyte Proxima dual-sensor haematological analyser device and its surrounding ecosystem—an at-home blood-testing platform that uses physics-informed AI to convert physical sensor signals into blood-test results delivered in minutes, paired with single-use CE-marked cartridges, a Bluetooth-connected companion mobile app (Health Hub), and a Clinician Dashboard with EHR integration capability. The offering targets healthcare providers (NHS, oncology, psychiatry, domiciliary care), payors, pharma, and individual consumers/families for regular decentralized immune monitoring.

Product overview

Oxford Immune Algorithmics offers Algocyte Proxima, a unified platform-plus-ecosystem architecture for at-home blood testing. The core product is the Algocyte Proxima dual-sensor haematological analyser, which pairs with the Algocyte Health Hub companion app (controlling the device via Bluetooth) and single-use CE-marked cartridges. Results are delivered to both the patient's phone app and the clinician's dashboard. The platform targets multiple care pathways including hospital-at-home, oncology, clozapine monitoring, and domiciliary care, with future capabilities for preventive and longevity health monitoring.

Differentiator

Problem solved

Functional benefit

Brands

• Algocyte Proxima: The main at-home blood testing device and system featuring dual-sensor haematological analyser technology.
• Algocyte Health Hub
• Algocyte Test Hub

Products and services

• Algocyte Proxima™ Dual-sensor haematological analyser device that brings blood testing into the home. Uses physics-informed AI to convert physical sensor signals into analyte measurements, with results delivered in minutes to a companion app and clinician dashboard. For healthcare providers (NHS, oncology, psychiatry, domiciliary care), payors, pharma, and individual consumers.
• Algocyte Health Hub (Companion App) Mobile companion application that guides users through each test, controls the Algocyte Proxima device via Bluetooth, receives results, and shares them with clinicians. A future release will learn user baseline and analyse trends against aggregated blood test data for differential diagnosis. For individual consumers and clinicians.
• Single-Use CE-Marked Cartridges (Test Kits) Single-use test cartridges that require no cold chain storage, designed for plug-and-play operation with the Algocyte Proxima device. Recurring consumable revenue tied to testing frequency. For users of the Algocyte Proxima system.
• Clinician Dashboard Web-based dashboard for clinicians to receive and review patient test results in minutes, with EHR integration capability for oncology pathways, online/offline sharing, and interpretation guidance. For healthcare providers and clinicians.

Segments7 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• National Health Service (NHS)coreStrategic or Co-development Partner · 1 January 2024Official partner of the NHS, featured on the NHS 75th anniversary book. The company has clinical leadership and research rooted in the NHS ecosystem, with the technology designed to support NHS care pathways and decentralized care models.
• Future Blood Testing Network+coreStrategic or Co-development PartnerKey partner in the UK's EPSRC research network awarded a grant to explore the future of blood testing. This partnership provides research validation and academic credibility for the company's technology.
• King's College LondoncoreStrategic or Co-development PartnerOxford Immune Algorithmics spun out from King's College London, indicating deep research collaboration and technology transfer from this academic institution.
• Oxford UniversitycoreStrategic or Co-development PartnerCompany was incubated at Oxford University, indicating research collaboration and technology development originating from this institution.
• Cambridge EcosystemminorStrategic or Co-development PartnerClinical leadership and research rooted in the Cambridge ecosystem, indicating secondary academic partnership for research and talent.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cue Health: Cue Health built a connected at-home molecular diagnostics platform with a hardware reader, single-use cartridges, and a companion app delivering lab-grade results in minutes. It is the closest functional analog to Algocyte Proxima's hardware-plus-AI-plus-app architecture for decentralized testing.
• Tasso: Tasso develops virtually painless at-home blood collection devices used in decentralized clinical trials and remote patient monitoring. It competes directly with OIA for home-based blood sampling workflows, particularly in pharma-sponsored DCT and oncology monitoring use cases.
• LetsGetChecked: LetsGetChecked offers a DTC and B2B home diagnostics platform combining self-collected samples, CE/FDA-regulated tests, and clinician-reviewed results. It competes with the consumer/employer side of Algocyte's value proposition and shares the recurring-testing business model.
• Thriva: Thriva is a UK-based home blood testing service offering subscription-based finger-prick panels with clinician review and trend tracking. It is the most direct UK geographic peer, sharing OIA's focus on regular at-home blood monitoring for preventive and chronic care.
• Everlywell: Everlywell sells a broad menu of at-home diagnostic tests (including full blood count panels) directly to consumers and through enterprise channels. It overlaps with OIA on consumer-facing home blood testing and recurring panel subscriptions.
• Healthy.io: Healthy.io turns smartphone cameras into clinical-grade urinalysis and wound-care diagnostics, with NHS and US health plan distribution. It shares OIA's strategy of converting consumer hardware into regulated diagnostic tools embedded in healthcare pathways.

Emerging players

• Yourbio Health: Yourbio Health developed the Tap device for virtually painless capillary blood collection, used in remote clinical trials and women's health. It overlaps with OIA on enabling remote blood sampling, though it focuses on collection rather than in-home analysis.

Broad incumbents

• iRhythm Technologies: iRhythm's Zio long-term cardiac monitor combines a wearable biosensor, an AI-based detection algorithm, and a clinician reporting service. It is an incumbent analog in the at-home biosensor-plus-AI diagnostic category, targeting continuous remote monitoring for cardiology.
• Labcorp OnDemand / Labcorp Pixel: Labcorp's consumer and employer-facing services (Pixel, OnDemand) sell self-collected blood panels with lab-processed results. It represents the incumbent central-lab workflow OIA is trying to displace with at-home point-of-care hematology.
• Siemens Healthineers (epoc / DCA): Siemens Healthineers manufactures point-of-care blood analyzers (epoc blood gas, DCA analyzers for HbA1c) widely used in hospital and near-patient settings. It is the broader incumbent in connected hematology / clinical-chemistry point-of-care devices that OIA is miniaturizing for the home.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/oia-algocyte

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford Immune Algorithmics